Registration Dossier

Administrative data

Description of key information

No data are available for the carcinogenicity of hexamethyldisilazane (HMDZ). However, further testing is not considered necessary because:
• The substance does not have a wide-dispersive use and exposure is expected to be low (see Section 9 for further details);
• The substance is not classified for mutagenicity; and
• There is no evidence from the repeated dose studies that the substance is able to induce hyperplasia or pre-neoplastic lesions.

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Justification for classification or non-classification

There are no data to suggest that HMDZ should be classified for carcinogenicity.